Novo Nordisk Foundation Center for Protein Research, University of Copenhagen , Blegdamsvej 3, DK-2200, Copenhagen, Denmark.
J Med Chem. 2017 Feb 9;60(3):886-898. doi: 10.1021/acs.jmedchem.6b00648. Epub 2017 Jan 23.
The G-protein-coupled receptor 39 (GPR39) is a G-protein-coupled receptor activated by Zn. We used a homology model-based approach to identify small-molecule pharmacological tool compounds for the receptor. The method focused on a putative binding site in GPR39 for synthetic ligands and knowledge of ligand binding to other receptors with similar binding pockets to select iterative series of minilibraries. These libraries were cherry-picked from all commercially available synthetic compounds. A total of only 520 compounds were tested in vitro, making this method broadly applicable for tool compound development. The compounds of the initial library were inactive when tested alone, but lead compounds were identified using Zn as an allosteric enhancer. Highly selective, highly potent Zn-independent GPR39 agonists were found in subsequent minilibraries. These agonists identified GPR39 as a novel regulator of gastric somatostatin secretion.
G 蛋白偶联受体 39(GPR39)是一种被 Zn 激活的 G 蛋白偶联受体。我们使用基于同源建模的方法来鉴定 GPR39 的小分子药理学工具化合物。该方法侧重于受体中假定的合成配体结合位点和对具有相似结合口袋的其他受体的配体结合的知识,以选择迭代的小型文库系列。这些文库从所有商业上可获得的合成化合物中精选。总共仅测试了 520 种化合物在体外,这使得该方法广泛适用于工具化合物的开发。初始文库中的化合物单独测试时没有活性,但使用 Zn 作为别构增强剂鉴定出了先导化合物。在随后的小型文库中发现了高度选择性、高活性的 Zn 非依赖性 GPR39 激动剂。这些激动剂将 GPR39 鉴定为胃生长抑素分泌的新型调节剂。